Regulatory Affairs

  1. Showing 80 results for:
  2. Regulatory Affairs
All Subjects

Advanced Therapy Medicinal Products (ATMPs) Classification 

Published by

Regulatory AffairsEarly Access SupportAdvanced TherapyATMPs Classification

Companies can consult the European Medicines Agency (EMA) to determine whether a medicine they are developing is an advanced therapy medicinal product (ATMP). This is an opportunity for ATMP developers to receive confirmation that a medicine, which is based on genes, cells or tissues, meets the scientific criteria for defining an ATMP. The procedure can help developers to clarify the applicable regulatory framework since the beginning of the product development.

View this resource Bookmark this resource

EMA Priority Medicines -PRIME scheme

Published by IRDiRC

Regulatory AffairsEarly Access SupportEarly ApprovalPriority Medicines Scheme

PRIME supports developers of medicines addressing an unmet medical need or which may bring major therapeutic advantage to patient with enhanced interaction and early dialogue to optimize the development of eligible medicines, improving clinical trial designs and speed up their evaluation and contribute to timely patients’ access. PRIME builds on the existing regulatory framework and tools already available such as scientific advice and accelerated assessment.

View this resource Bookmark this resource

FDA Expedited Program for serious conditions – Breakthrough Therapy Designation

Published by IRDiRC

Regulatory AffairsEarly Access SupportRegulatory AdviceExpedited ProgrammeBreakthrough Therapy Designation

Process designed to facilitate the development and expedite the review of drugs intended to treat a serious condition AND preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).

View this resource Bookmark this resource

Joint EMA-FDA Scientific Advice

Published by IRDiRC

Regulatory AffairsEarly Access SupportScientific AdviceJoint EMA-FDA Scientific Advice

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services have a program to provide parallel scientific advice (PSA) to sponsors. The goal of the PSA program is to provide a mechanism for EMA assessors and FDA reviewers to concurrently exchange with sponsors their views on scientific issues during the development phase of new medicinal products (i.e., new human drugs and Biologics).

View this resource Bookmark this resource